Our Focus
new molecules, LOW-COST of goods and
ground breaking drug delivery systems
Alterola Biotech is a pharma company working with cannabinoid and
cannabinoid-like molecules.
Achieving a low cost of goods for GMP grade API will mean that the company can service high volume indications, as well as orphan indications. To date, due to the high cost of goods, most pharmaceutical companies have focused on low volume (high price) orphan indications.
Bringing down the cost of goods (and improving delivery) opens up a much bigger market for other cannabinoid and cannabinoid-like medicines.
The company has three areas of focus.
1
Pharmaceutical development
Developing cannabinoid and cannabinoid-like
medicines across a range of indications for humans and animals.
2
IMPROVED DRUG DELIVERY
Our exclusive licence with Nano4M Ltd seeks to utilise the nano-formulation use of nano-formulation technologies to greatly improve the bio-availability of both the cannabinoids and cannabinoid-like molecules.
3
Low Cost of goods
Achieving a low cost of goods for GMP grade Active Pharmaceutical Ingredient (API) means that the company will be able to service high volume indications, as well as orphan indications.
DEVELOPING NEW CANNABINOID AND CANNABINOID-LIKE MEDICINES
